This technology is a method of using metabolic profiling-related biomarkers to identify newborns or infants with autism spectrum disorder for early intervention.
This technology is a programmable peptide microarray, that identifies immunogenic epitopes for differential serodiagnosis for a broad range of highly pathogenic microbial agents, including high-threat hemorrhagic fever viruses.
